Showing 3231-3240 of 10731 results for "".
- Research on Nitric Oxide-Releasing Nanoparticles Reveals Promising Skin Infection Treatmenthttps://practicaldermatology.com/news/research-on-nitric-oxide-releasing-nanoparticles-reveals-promising-skin-infection-treatment/2458095/George Washington University (GW) researchers have found that topically applied nitric oxide-releasing nanoparticles (NO-np) are a viable treatment for deep fungal infections of the skin caused by dermatophyt
- MKTP Surgery Shows Long-Term Benefit for Restoring Skin Pigmentation in Vitiligohttps://practicaldermatology.com/news/mktp-surgery-shows-long-term-benefit-for-restoring-skin-pigmentation-in-vitiligo/2458103/Melanocyte-keratinocyte transplantation (MKTP) provides long-term benefits for restoring skin pigmentation caused by vitiligo, report researchers from Henry Ford Hospital in Detroit. “MKTP works and it lasts a long time,” says Iltefat Hamzavi, M.D., a Henry Ford dermatologist
- Cutanea Life Sciences Unveils Facing Forward Mobile App for Acne Patientshttps://practicaldermatology.com/news/cutanea-life-sciences-unveils-facing-forward-new-mobile-app-for-acne-patients/2458104/Cutanea Life Sciences, Inc. introduced its Facing Forward mobile application for patients who are prescribed Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The app will be available free thro
- Valeant Launches Siliq Injection for Psoriasishttps://practicaldermatology.com/news/valeant-launches-siliq-injection-for-psoriasis/2458107/Valeant Pharmaceuticals International, Inc. launched Siliq (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York from July 27-30, 2017. Siliq, a
- Study IDs Risk Factors for Melanoma in Kidney Transplant Recipientshttps://practicaldermatology.com/news/study-ids-risk-factors-for-melanoma-in-kidney-transplant-recipients/2458108/Kidney transplant patients appear to be at a greater risk of developing melanoma than the general population and risk factors include being older, male and white, findings that corroborate results demonstrated in other studies, according to a new article published by
- Innovation in Action: Meet the DNA Sunscreen that Gets Better the Longer You Wear Ithttps://practicaldermatology.com/news/innovation-in-action-meet-a-dna-sunscreen-that-gets-better-the-longer-you-wear-it/2458109/Researchers at Binghamton University, State University of New York have developed a coating made out of DNA that gets better at protecting skin from Ultraviolet light the more you expose it to the sun, and it also keeps your skin hydrated. “Ultraviolet (UV) light can actually damage
- Early Use of CO2 Lasers on Surgical Scars Bests Silicone Gel Treatmenthttps://practicaldermatology.com/news/early-use-of-co2-lasers-on-surgical-scars-bests-silicone-gel-treatment/2458112/Early treatment of surgical scars with a super-pulsed fractional C02 laser shows promise, new research suggests. The study, which appears in Lasers in Surgery and Medicine (LSM), found that laser treatment of
- DermTech Secures Billing Codes for its Proprietary Melanoma Testhttps://practicaldermatology.com/news/dermtech-secures-billing-codes-for-its-proprietary-melanoma-test/2458115/The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAM
- Valeant to Sell Obagi Medical Products Business for $190 Mhttps://practicaldermatology.com/news/valeant-to-sell-obagi-medical-products-business-for-190-m/2458117/Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic ma
- Paratek: Phase 3 Study of Oral-Only Dosing of Omadacycline Met FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infectionshttps://practicaldermatology.com/news/paratek-phase-3-study-of-oral-only-dosing-of-omadacycline-met-fda-and-ema-efficacy-endpoints-in-acute-bacterial-skin-infections/2458118/Paratek Pharmaceuticals, Inc. shared positive top-line results from a pivotal Phase 3 study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The study met all of